zika
viru
zikv
mosquitoborn
flaviviru
attract
global
attent
due
close
associ
congenit
zika
syndrom
neurolog
diseas
transmiss
addit
rout
sexual
contact
current
vaccin
approv
zikv
thu
urgent
need
develop
effect
safe
zikv
vaccin
domain
iii
diii
zikv
envelop
e
protein
import
vaccin
target
vaccin
develop
use
mutant
diii
e
ediii
protein
protect
adult
pregnant
mice
unborn
offspr
zikv
infect
use
immunocompet
balbc
mice
treat
receptor
antibodi
investig
whether
three
adjuv
aluminum
alum
monophosphoryl
lipid
mpl
either
alon
combin
could
improv
efficaci
ediii
subunit
vaccin
data
show
although
vaccin
formul
singl
adjuv
induc
specif
antibodi
cellular
immun
respons
reduc
viral
load
mice
challeng
zikv
combin
alum
mpl
adjuv
led
robust
balanc
immun
respons
stronger
neutral
activ
three
recent
zikv
human
strain
greater
protect
highdos
zikv
challeng
particularli
combin
alum
mpl
significantli
reduc
viral
titer
viral
rna
copi
number
sera
tissu
includ
male
reproduct
organ
overal
studi
identifi
combin
alum
mpl
effect
adjuv
zikv
ediii
subunit
vaccin
import
implic
subunit
vaccin
envelop
virus
includ
nonzikv
flavivirus
vaccin
microcephali
fetal
demis
congenit
disord
thu
zikv
emerg
global
health
threat
urgent
requir
effect
vaccin
combat
zikvassoci
diseas
zikv
genom
encod
singl
polyprotein
process
three
structur
protein
capsid
c
precursor
membranemembran
prmm
envelop
e
seven
nonstructur
protein
e
protein
import
role
infect
pathogenesi
involv
viru
bind
target
cell
membran
fusion
also
serv
import
vaccin
target
e
protein
transmembran
protein
consist
three
domain
term
ii
iii
didiii
fusion
loop
fl
stalk
region
didii
region
zikv
e
protein
target
crossreact
antibodi
flavivirus
dengu
viru
denv
west
nile
viru
wnv
wherea
diii
domain
induc
zikvspecif
antibodi
therefor
key
target
zikv
vaccin
develop
zikv
vaccin
candid
develop
includ
inactiv
viru
live
attenu
viru
dna
mrna
viral
vector
viruslik
particl
vlp
viral
protein
subunit
vaccin
although
mani
advanc
clinic
trial
test
immunogen
andor
level
protect
none
approv
use
human
thu
continu
effort
requir
develop
safe
efficaci
zikv
vaccin
subunit
vaccin
contain
live
viru
normal
elicit
advers
side
effect
safe
use
human
includ
pregnant
women
unborn
offspr
howev
subunit
vaccin
often
suffer
low
immunogen
although
may
improv
adjuv
adjuv
import
compon
vaccin
enhanc
immunogen
vaccin
antigen
boost
qualiti
durat
humor
andor
cellular
immun
respons
aluminum
salt
alum
approv
use
adjuv
human
vaccin
us
also
key
compon
vaccin
number
virus
includ
hepat
viru
hav
hepat
b
viru
hbv
human
papilloma
viru
hpv
alum
adjuv
commonli
use
licens
vaccin
alum
hydroxid
alum
phosphat
monophosphoryl
lipid
mpl
nontox
deriv
lipopolysaccharid
lp
tolllik
receptor
tlr
agonist
also
use
adjuv
human
vaccin
addit
combin
alum
mpl
use
vaccin
hbv
hpv
oilinwat
emuls
approv
use
conjug
vaccin
number
virus
includ
influenza
viru
herp
simplex
viru
hsv
human
immunodefici
viru
hiv
previous
shown
zikv
e
protein
diiibas
subunit
vaccin
fuse
fc
region
human
igg
induc
specif
neutral
antibodi
diverg
zikv
strain
furthermor
mask
nonneutr
epitop
center
residu
protein
glycan
probe
diii
e
ediii
enhanc
neutral
antibodi
respons
increas
protect
adult
pregnant
mice
zikv
challeng
without
impact
fetal
develop
use
ediiibas
subunit
vaccin
compar
adjuvant
alum
mpl
alum
mpl
combin
refer
hope
identifi
adjuv
adjuv
combin
abl
promot
ediiibas
zikv
vaccin
induc
balanc
immun
respons
potent
protect
zikv
infect
result
show
balanc
immun
respons
gener
immunogen
abil
protect
zikv
infect
significantli
enhanc
alum
mpl
use
vaccin
formul
studi
identifi
combin
alum
mpl
effect
adjuv
formul
zikv
ediiibas
subunit
vaccin
materi
method
fourtofiveweekold
male
balbc
mice
use
studi
anim
studi
carri
strict
accord
recommend
guid
care
use
zika
viru
zikv
mosquitoborn
flaviviru
first
isol
rhesu
macaqu
uganda
zikv
infect
asymptomat
show
mild
clinic
symptom
fever
headach
rash
howev
adult
infect
zikv
present
syndrom
gb
disord
nervou
system
result
muscl
weak
andor
paralysi
addit
infect
pregnanc
may
caus
congenit
zika
syndrom
cz
associ
laboratori
anim
nation
research
council
committe
protocol
approv
institut
anim
care
use
committe
iacuc
new
york
blood
center
permit
number
protein
prepar
previous
describ
briefli
zikv
diii
e
protein
contain
mutat
residu
e
protein
hereinaft
ediii
construct
use
mutagenesi
kit
thermo
fisher
scientif
waltham
usa
zikv
wildtyp
plasmid
express
residu
diii
e
protein
ctermin
fc
tag
human
hfc
recombin
ediii
protein
transient
express
cultur
supernat
cell
purifi
protein
affin
chromatographi
ge
healthcar
chicago
il
usa
purifi
zikv
ediii
protein
use
immun
mice
presenc
absenc
variou
adjuv
previous
describ
briefli
mice
intramuscularli
im
immun
ediii
protein
one
follow
adjuv
alum
ie
aluminum
hydroxid
invivogen
san
diego
ca
usa
mpl
invivogen
alum
mpl
mice
inject
ediii
protein
phosphatebuff
salin
pb
includ
control
immun
mice
boost
immunogen
three
week
sera
collect
day
postlast
dose
detect
antibodi
respons
neutral
antibodi
describ
zikv
e
ediii
hfcspecif
antibodi
immun
mous
sera
analyz
elisa
previous
describ
briefli
elisa
plate
coat
zikv
ediii
protein
zikv
fulllength
e
protein
tag
aviva
system
biolog
san
diego
ca
usa
ctermin
hfcfuse
control
protein
contain
receptorbind
domain
ie
rbdfc
middl
east
respiratori
syndrom
coronaviru
merscov
spike
protein
overnight
c
block
fatfre
milk
pbst
pb
contain
c
h
plate
wash
pbst
time
sequenti
incub
serial
dilut
mous
sera
horseradish
peroxidas
hrp
conjug
antimous
igg
iggfab
antizikv
antihfc
antibodi
antibodi
thermo
fisher
scientif
c
h
reaction
visual
addit
tetramethylbenzidin
substrat
sigma
st
loui
mo
usa
stop
h
absorb
nm
measur
use
elisa
plate
reader
tecan
morrisvil
nc
usa
three
recent
zikv
human
strain
includ
rico
use
studi
briefli
virus
grown
vero
cell
detect
viral
titer
use
plaqueform
assay
mous
sera
tissu
mg
eye
mg
heart
spleen
muscl
brain
collect
day
postchalleng
also
detect
zikv
titer
describ
detect
limit
plaqueform
unit
pfu
ml
sera
pfug
eye
pfug
heart
spleen
muscl
brain
tissu
neutral
antibodi
immun
mous
sera
detect
prnt
previous
describ
briefli
pfu
zikv
incub
serial
dilut
mous
sera
c
h
ad
vero
cell
incub
c
h
cell
overlaid
dmem
contain
carboxymethyl
cellulos
fb
cultur
c
day
stain
crystal
violet
neutral
titer
base
serum
neutral
plaqu
reduct
prnt
calcul
use
calcusyn
comput
program
immun
mice
challeng
zikv
previous
describ
briefli
nine
day
postlast
immun
zikv
ediii
protein
without
respect
adjuv
pb
control
mice
pretreat
block
receptor
antibodi
mgmous
leinco
technolog
fenton
mo
usa
h
later
intraperiton
ip
challeng
zikv
strain
pfu
mous
splenocyt
isol
day
postchalleng
detect
cellular
immun
respons
use
flow
cytometri
analysi
mous
sera
tissu
collect
describ
detect
zikv
titer
rna
copi
use
plaqueform
assay
quantit
revers
transcriptas
pcr
qrtpcr
respect
flow
cytometri
analysi
perform
detect
zikvspecif
cellular
immun
respons
previous
describ
briefli
splenocyt
cellswel
isol
immun
mice
day
postzikv
challeng
treat
red
blood
cell
lysi
buffer
biolegend
san
diego
ca
usa
follow
incub
zikv
ediii
peptid
mixtur
final
concentr
tabl
presenc
brefeldin
biolegend
cultur
c
h
stimul
cell
wash
pb
stain
surfac
marker
use
antimous
fitcantimous
antimous
antibodi
biolegend
fixat
permeabil
cell
stain
intracellular
marker
use
pe
antimous
interferongamma
brilliant
violet
tm
antimous
interleukin
brilliant
violet
tm
antimous
antibodi
biolegend
analyz
use
flow
cytomet
bd
lsrfortessa
system
assay
perform
detect
zikv
rna
copi
sera
tissu
challeng
mice
previous
describ
briefli
qiaamp
minelut
viru
spin
kit
rneasi
mini
kit
qiagen
germantown
md
usa
use
extract
rna
sera
tissu
respect
quantifi
qrtpcr
use
power
sybr
green
pcr
master
mix
ambion
rnase
inhibitor
multiscrib
revers
transcriptas
thermo
fisher
scientif
viia
master
cycler
pcr
system
thermo
fisher
scientif
forward
primer
revers
primer
appli
amplif
qrtpcr
standard
curv
made
via
serial
dilut
recombin
plasmid
express
zikv
membran
e
protein
linear
standard
curv
rang
rna
copi
correl
coeffici
r
valu
detect
limit
rna
copi
select
calcul
zikv
rna
copi
test
sampl
mous
sera
tissu
includ
eye
heart
spleen
mg
muscl
testi
mg
collect
day
postchalleng
detect
zikv
rna
detect
limit
rna
copiesml
sera
rna
copiesg
eye
heart
spleen
rna
copiesg
muscl
testi
valu
express
mean
standard
error
mean
sem
statist
signific
data
among
differ
group
calcul
use
oneway
anova
tukey
multipl
comparison
test
base
graphpad
prism
statist
softwar
indic
p
p
p
respect
comparison
adjuvant
alum
mpl
combin
immun
zikv
ediii
compar
potenc
adjuv
balbc
mice
immun
zikv
nonneutr
epitopemask
ediii
subunit
vaccin
presenc
absenc
alum
mpl
alum
adjuv
combin
mpl
adjuv
addit
includ
control
adjuv
seven
day
follow
second
dose
sera
collect
antibodi
titer
specif
zikv
ediii
contain
ctermin
hfc
tag
e
without
fusion
hfc
determin
figur
use
without
adjuv
ediii
immunogen
induc
ediiispecif
igg
antibodi
total
igg
inclus
alum
adjuv
significantli
improv
antibodi
respons
although
mpl
appear
enhanc
antibodi
respons
ediii
use
combin
alum
antibodi
respons
significantli
higher
ediii
alum
alon
figur
sinc
ediii
protein
fuse
hfc
tag
igg
antibodi
target
hfc
also
gener
show
similar
trend
specif
ediii
figur
nevertheless
coat
elisa
plate
zikv
fulllength
e
protein
without
hfc
significantli
hightit
igg
antibodi
induc
particularli
alum
mpladjuv
ediii
figur
suggest
fusion
hfc
ediii
subunit
vaccin
affect
gener
zikvspecif
igg
antibodi
multipl
comparison
test
base
graphpad
prism
statist
softwar
indic
p
p
p
respect
compar
potenc
adjuv
balbc
mice
immun
zikv
nonneutr
epitopemask
ediii
subunit
vaccin
presenc
absenc
alum
mpl
alum
adjuv
combin
mpl
adjuv
addit
includ
control
adjuv
seven
day
follow
second
dose
sera
collect
antibodi
titer
specif
zikv
ediii
contain
ctermin
hfc
tag
e
without
fusion
hfc
determin
figur
use
without
adjuv
ediii
immunogen
induc
ediiispecif
igg
antibodi
total
igg
inclus
alum
adjuv
significantli
improv
antibodi
respons
although
mpl
appear
enhanc
antibodi
respons
ediii
use
combin
alum
antibodi
respons
significantli
higher
ediii
alum
alon
figur
sinc
ediii
protein
fuse
hfc
tag
igg
antibodi
target
hfc
also
gener
show
similar
trend
specif
ediii
figur
nevertheless
coat
elisa
plate
zikv
fulllength
e
protein
without
hfc
significantli
hightit
igg
antibodi
induc
particularli
alum
mpladjuv
ediii
figur
suggest
fusion
hfc
ediii
subunit
vaccin
affect
gener
zikvspecif
igg
antibodi
immun
challeng
schedul
mice
immun
intramuscularli
im
pb
background
control
zikv
ediii
without
adjuv
aluminum
salt
alum
monophosphoryl
lipid
mpl
alum
mpl
adjuv
boost
day
initi
dose
sera
collect
seven
day
boost
day
use
determin
zikv
e
ediiispecif
antibodi
neutral
antibodi
level
mice
inject
receptor
antibodi
order
becom
suscept
subsequ
zikv
infect
nine
day
boost
day
subsequ
challeng
zikv
strain
plaqueform
unit
pfu
follow
day
day
sera
tissu
sampl
collect
three
day
postchalleng
day
use
determin
zikv
titer
viral
load
rna
copi
splenocyt
also
test
zikv
ediiispecif
cellular
immun
respons
immun
challeng
schedul
mice
immun
intramuscularli
im
pb
background
control
zikv
ediii
without
adjuv
aluminum
salt
alum
monophosphoryl
lipid
mpl
alum
mpl
adjuv
boost
day
initi
dose
sera
collect
seven
day
boost
day
use
determin
zikv
e
ediiispecif
antibodi
neutral
antibodi
level
mice
inject
receptor
antibodi
order
becom
suscept
subsequ
zikv
infect
nine
day
boost
day
subsequ
challeng
zikv
strain
plaqueform
unit
pfu
follow
day
day
sera
tissu
sampl
collect
three
day
postchalleng
day
use
determin
zikv
titer
viral
load
rna
copi
splenocyt
also
test
zikv
ediiispecif
cellular
immun
respons
combin
alum
mpl
adjuv
induc
significantli
higher
antibodi
titer
either
alum
mpl
alon
adjuv
figur
e
use
combin
mpl
alum
adjuv
induc
balanc
antibodi
respons
indic
low
ratio
contrast
alum
gener
antibodi
respons
ediii
alon
formul
show
slight
bia
figur
data
demonstr
combin
alum
mpl
adjuv
enhanc
level
ediiispecif
igg
antibodi
produc
balanc
igg
respons
next
compar
level
antizikv
neutral
antibodi
induc
ediii
vaccin
formul
differ
adjuv
end
sera
collect
seven
day
immun
second
dose
ediii
test
neutral
three
human
zikv
also
determin
level
antibodi
induc
ediii
seven
day
second
dose
ediii
alon
induc
good
respons
respons
notic
weaker
figur
e
use
alon
alum
induc
higher
level
antibodi
ediii
without
adjuv
mpl
induc
significantli
higher
level
antibodi
use
combin
alum
mpl
significantli
improv
abil
ediii
induc
antibodi
respons
figur
e
moreov
combin
alum
mpl
adjuv
induc
significantli
higher
antibodi
titer
either
alum
mpl
alon
adjuv
figur
e
use
combin
mpl
alum
adjuv
induc
balanc
antibodi
respons
indic
low
ratio
contrast
alum
gener
antibodi
respons
ediii
alon
formul
show
slight
bia
figur
data
demonstr
combin
alum
mpl
adjuv
enhanc
level
ediiispecif
igg
antibodi
produc
balanc
igg
respons
next
compar
level
antizikv
neutral
antibodi
induc
ediii
vaccin
formul
differ
adjuv
end
sera
collect
seven
day
immun
second
dose
ediii
test
neutral
three
human
zikv
strain
vaccin
three
strain
alum
mpl
adjuv
induc
significantli
stronger
neutral
antibodi
respons
ediii
alon
mpl
enhanc
neutral
antibodi
respons
strain
figur
importantli
three
zikv
strain
neutral
antibodi
titer
induc
ediii
significantli
higher
alum
use
combin
mpl
alum
mpl
sole
adjuv
figur
contrast
sera
inject
pb
induc
backgroundlevel
neutral
antibodi
figur
data
show
although
singl
adjuv
increas
antizikv
neutral
antibodi
respons
combin
alum
mpl
adjuv
consist
induc
highest
level
neutral
antibodi
zikv
strain
investig
vaccin
x
strain
three
strain
alum
mpl
adjuv
induc
significantli
stronger
neutral
antibodi
respons
ediii
alon
mpl
enhanc
neutral
antibodi
respons
strain
figur
importantli
three
zikv
strain
neutral
antibodi
titer
induc
ediii
significantli
higher
alum
use
combin
mpl
alum
mpl
sole
adjuv
figur
contrast
sera
inject
pb
induc
backgroundlevel
neutral
antibodi
figur
data
show
although
singl
adjuv
increas
antizikv
neutral
antibodi
respons
combin
alum
mpl
adjuv
consist
induc
highest
level
neutral
antibodi
zikv
strain
investig
splenocyt
isol
immun
mice
three
day
zikv
challeng
strain
use
investig
adjuv
enhanc
zikv
ediiispecif
cellular
immun
respons
specif
determin
level
secret
cell
cell
cell
subset
low
level
cytokin
detect
mice
immun
ediii
alon
figur
e
suggest
ediii
without
adjuv
induc
strong
ediiispecif
cell
respons
use
individu
alum
increas
secret
cell
increas
express
seen
mpl
figur
c
cell
inclus
alum
significantli
increas
express
express
increas
alum
figur
e
use
combin
alum
mpl
adjuv
significantli
enhanc
express
cytokin
test
cell
observ
adjuv
alum
mpl
andor
use
individu
figur
b
e
data
indic
although
individu
adjuv
enhanc
ediiispecif
cellular
immun
respons
combin
alum
mpl
greater
effect
particularli
cell
figur
detect
neutral
antibodi
titer
immun
mous
sera
sera
collect
seven
day
follow
second
dose
ediii
test
plaqu
reduct
neutral
test
prnt
assay
neutral
antibodi
zikv
human
strain
b
c
pb
show
background
level
neutral
antibodi
neutral
activ
indic
adjuv
present
neutral
antibodi
titer
base
serum
neutral
plaqu
reduct
prnt
data
express
mean
sem
n
signific
differ
p
p
p
among
differ
group
shown
splenocyt
isol
immun
mice
three
day
zikv
challeng
strain
use
investig
adjuv
enhanc
zikv
ediiispecif
cellular
immun
respons
specif
determin
level
secret
cell
cell
cell
subset
low
level
cytokin
detect
mice
immun
ediii
alon
figur
e
suggest
ediii
without
adjuv
induc
strong
ediiispecif
cell
respons
use
individu
alum
increas
secret
cell
increas
express
seen
mpl
figur
c
cell
inclus
alum
significantli
increas
express
express
increas
alum
figur
e
use
combin
alum
mpl
adjuv
significantli
enhanc
express
cytokin
test
cell
observ
adjuv
alum
mpl
andor
use
individu
figur
b
e
data
indic
although
individu
adjuv
enhanc
ediiispecif
cellular
immun
respons
combin
alum
mpl
greater
effect
particularli
cell
investig
adjuv
increas
protect
zikv
infect
immun
mice
challeng
highdos
zikv
strain
pfumous
one
day
administ
antibodi
figur
viral
load
determin
plaqueform
assay
zikv
rna
copi
number
determin
qrtpcr
assay
use
sera
tissu
collect
three
day
postchalleng
optim
time
point
detect
zikv
infect
antibodytr
immunocompet
mice
includ
balbc
unpublish
data
similar
level
zikv
seen
sera
tissu
eye
heart
spleen
muscl
mice
immun
ediii
without
adjuv
pb
figur
e
wherea
brain
tissu
signific
reduct
viral
titer
observ
mice
immun
ediii
alon
figur
result
suggest
immun
ediii
unabl
elicit
adequ
protect
zikv
challeng
mice
immun
ediii
formul
singl
adjuv
alum
mpl
andor
significantli
reduc
viral
titer
compar
immun
ediii
alon
sera
heart
spleen
muscl
brain
figur
cf
immun
pb
sera
eye
heart
spleen
muscl
brain
figur
suggest
inclus
adjuv
increas
protect
importantli
sera
tissu
test
combin
alum
mpl
adjuv
result
significantli
lower
undetect
viral
titer
immun
condit
singl
adjuv
alum
mpl
andor
figur
result
demonstr
although
singl
adjuv
increas
protect
greatest
level
protect
highdos
zikv
challeng
achiev
ediii
vaccin
formul
alum
mpl
adjuv
investig
adjuv
increas
protect
zikv
infect
immun
mice
challeng
highdos
zikv
strain
pfumous
one
day
administ
antibodi
figur
viral
load
determin
plaqueform
assay
zikv
rna
copi
number
determin
qrtpcr
assay
use
sera
tissu
collect
three
day
postchalleng
optim
time
point
detect
zikv
infect
antibodytr
immunocompet
mice
includ
balbc
unpublish
data
similar
level
zikv
seen
sera
tissu
eye
heart
spleen
muscl
mice
immun
ediii
without
adjuv
pb
figur
wherea
brain
tissu
signific
reduct
viral
titer
observ
mice
immun
ediii
alon
figur
result
suggest
immun
ediii
unabl
elicit
adequ
protect
zikv
challeng
mice
immun
ediii
formul
singl
adjuv
alum
mpl
andor
significantli
reduc
viral
titer
compar
immun
ediii
alon
sera
heart
spleen
muscl
brain
figur
cf
immun
pb
sera
eye
heart
spleen
muscl
brain
figur
suggest
inclus
adjuv
increas
protect
importantli
sera
tissu
test
combin
alum
mpl
adjuv
result
significantli
lower
undetect
viral
titer
immun
condit
singl
adjuv
alum
mpl
andor
figur
result
demonstr
although
singl
adjuv
increas
protect
greatest
level
protect
highdos
zikv
challeng
achiev
ediii
vaccin
formul
alum
mpl
adjuv
brain
f
sera
tissu
collect
three
day
postchalleng
zikv
strain
viral
load
determin
plaqueform
assay
mice
immun
pb
serv
control
detect
limit
sampl
pfuml
sera
pfug
eye
pfug
heart
spleen
muscl
brain
data
express
mean
sem
n
signific
differ
p
p
p
among
differ
group
shown
consist
viral
load
mice
immun
ediii
alon
slightli
lower
level
zikv
rna
sera
tissu
eye
spleen
compar
immun
pb
figur
b
confirm
adjuv
requir
induc
protect
similarli
inclus
singl
adjuv
alum
mpl
andor
result
significantli
lower
level
zikv
rna
sera
tissu
eye
heart
spleen
muscl
compar
immun
ediii
alon
figur
furthermor
level
zikv
rna
sera
tissu
alum
mpl
adjuv
use
combin
immun
significantli
lower
singl
adjuv
alum
mpl
andor
use
figur
result
consist
level
viral
load
figur
confirm
protect
zikv
greatest
alum
mpl
adjuv
use
combin
zikv
replic
reproduct
organ
long
period
therefor
also
determin
amount
zikv
rna
test
immun
challeng
mice
similar
result
tissu
inclus
singl
adjuv
reduc
level
viral
rna
immun
ediii
alon
pb
figur
moreov
viral
rna
copi
lowest
testi
mice
receiv
ediii
formul
alum
mpl
combin
figur
importantli
result
show
formul
ediii
combin
alum
mpl
adjuv
reduc
viral
rna
copi
male
reproduct
organ
figur
detect
zikv
titer
challeng
sera
eye
b
heart
c
spleen
muscl
e
brain
f
sera
tissu
collect
three
day
postchalleng
zikv
strain
viral
load
determin
plaqueform
assay
mice
immun
pb
serv
control
detect
limit
sampl
pfuml
sera
pfug
eye
pfug
heart
spleen
muscl
brain
data
express
mean
sem
n
signific
differ
p
p
p
among
differ
group
shown
consist
viral
load
mice
immun
ediii
alon
slightli
lower
level
zikv
rna
sera
tissu
eye
spleen
compar
immun
pb
figur
b
confirm
adjuv
requir
induc
protect
similarli
inclus
singl
adjuv
alum
mpl
andor
result
significantli
lower
level
zikv
rna
sera
tissu
eye
heart
spleen
muscl
compar
immun
ediii
alon
figur
furthermor
level
zikv
rna
sera
tissu
alum
mpl
adjuv
use
combin
immun
significantli
lower
singl
adjuv
alum
mpl
andor
use
figur
result
consist
level
viral
load
figur
confirm
protect
zikv
greatest
alum
mpl
adjuv
use
combin
figur
detect
zikv
rna
challeng
sera
eye
b
heart
c
spleen
muscl
e
testi
f
sera
tissu
collect
three
day
postchalleng
zikv
strain
viral
rna
copi
determin
qrtpcr
mice
immun
pb
serv
control
detect
limit
rna
copiesml
sera
rna
copiesg
eye
heart
spleen
rna
copiesg
muscl
testi
data
express
mean
sem
n
signific
differ
p
p
p
among
differ
group
shown
proteinbas
subunit
vaccin
gener
safer
vaccin
base
live
attenu
inactiv
virus
usual
low
immunogen
efficaci
howev
vaccin
perform
improv
structurebas
design
via
mask
nonneutr
unfavor
epitop
via
antigen
conjug
addit
choic
adjuv
greatli
influenc
immunogen
efficaci
vaccin
includ
subunit
vaccin
previou
studi
demonstr
mask
nonneutr
epitop
surround
residu
zikv
diii
e
protein
subunit
vaccin
ie
ediii
improv
immunogen
protect
adult
pregnant
mice
unborn
offspr
zikv
infect
extend
studi
investig
influenc
licens
adjuv
immunogen
protect
mice
highdos
zikv
challeng
follow
immun
ediii
subunit
vaccin
vaccin
prepar
singl
adjuv
alum
mpl
significantli
improv
antibodi
respons
total
igg
andor
immun
without
adjuv
howev
highest
igg
titer
obtain
alum
mpl
use
combin
state
adjuv
influenc
immun
respons
vaccin
alum
potent
induc
immun
respons
similarli
gener
induc
slightlybias
respons
seen
vaccin
influenza
viru
merscov
contrast
mpl
induc
express
therefor
bia
gener
balanc
immun
respons
moreov
combin
mpl
alum
adjuv
ie
may
shift
immun
respons
gener
balanc
immun
figur
detect
zikv
rna
challeng
sera
eye
b
heart
c
spleen
muscl
e
testi
f
sera
tissu
collect
three
day
postchalleng
zikv
strain
viral
rna
copi
determin
qrtpcr
mice
immun
pb
serv
control
detect
limit
rna
copiesml
sera
rna
copiesg
eye
heart
spleen
rna
copiesg
muscl
testi
data
express
mean
sem
n
signific
differ
p
p
p
among
differ
group
shown
zikv
replic
reproduct
organ
long
period
therefor
also
determin
amount
zikv
rna
test
immun
challeng
mice
similar
result
tissu
inclus
singl
adjuv
reduc
level
viral
rna
immun
ediii
alon
pb
figur
moreov
viral
rna
copi
lowest
testi
mice
receiv
ediii
formul
alum
mpl
combin
figur
importantli
result
show
formul
ediii
combin
alum
mpl
adjuv
reduc
viral
rna
copi
male
reproduct
organ
proteinbas
subunit
vaccin
gener
safer
vaccin
base
live
attenu
inactiv
virus
usual
low
immunogen
efficaci
howev
vaccin
perform
improv
structurebas
design
via
mask
nonneutr
unfavor
epitop
via
antigen
conjug
addit
choic
adjuv
greatli
influenc
immunogen
efficaci
vaccin
includ
subunit
vaccin
previou
studi
demonstr
mask
nonneutr
epitop
surround
residu
zikv
diii
e
protein
subunit
vaccin
ie
ediii
improv
immunogen
protect
adult
pregnant
mice
unborn
offspr
zikv
infect
extend
studi
investig
influenc
licens
adjuv
immunogen
protect
mice
highdos
zikv
challeng
follow
immun
ediii
subunit
vaccin
vaccin
prepar
singl
adjuv
alum
mpl
significantli
improv
antibodi
respons
total
igg
andor
immun
without
adjuv
howev
highest
igg
titer
obtain
alum
mpl
use
combin
state
adjuv
influenc
immun
respons
vaccin
alum
potent
induc
immun
respons
similarli
gener
induc
slightlybias
respons
seen
vaccin
influenza
viru
merscov
contrast
mpl
induc
express
therefor
bia
gener
balanc
immun
respons
moreov
combin
mpl
alum
adjuv
ie
may
shift
immun
respons
gener
balanc
immun
respons
consist
observ
found
alum
use
individu
adjuv
ediii
induc
immun
respons
mpl
sole
adjuv
use
combin
alum
balanc
immun
respons
gener
humor
cellular
immun
respons
influenc
zikv
pathogenesi
play
key
role
control
zikv
replic
particular
neutral
antibodi
induc
zikv
vaccin
may
block
infect
cell
secret
cytokin
promot
antibodi
product
directli
kill
infect
cell
cell
critic
protect
zikv
infect
mice
nonhuman
primat
human
current
studi
observ
alum
mpl
adjuv
enhanc
product
antizikv
neutral
antibodi
howev
combin
alum
mpl
gener
significantli
higher
neutral
antibodi
titer
individu
use
adjuv
result
consist
three
emerg
human
zikv
strain
addit
alum
mpl
use
combin
enhanc
secret
particularli
cell
viral
vaccin
eg
hbv
hpv
formul
combin
alum
mpl
adjuv
ie
stimul
antigenspecif
b
cell
result
stronger
antibodi
includ
neutral
antibodi
cellular
respons
vaccin
formul
use
alum
alon
use
zikv
ediii
protein
model
antigen
studi
confirm
observ
show
combin
alum
mpl
adjuv
enhanc
immunogen
ediii
observ
singl
adjuv
figur
wherea
alum
mpl
combin
alon
without
ediii
unabl
elicit
zikvspecif
immun
respons
protect
zikv
infect
zikv
normal
infect
immunocompet
mice
includ
balbc
infect
immunocompromis
mice
defici
interferon
receptor
receptor
ifnar
receptor
carri
challeng
studi
use
balbc
mice
treat
antibodi
also
render
mice
suscept
zikv
infect
formul
ediii
individu
adjuv
improv
protect
highdos
zikv
challeng
consist
viru
neutral
studi
result
combin
alum
mpl
significantli
improv
protect
confirm
show
combin
alum
mpl
adjuv
significantli
reduc
viral
titer
viral
rna
copi
sera
tissu
compar
immun
regim
zikv
transmit
sexual
contact
viru
persist
femal
male
test
semin
vesicl
reproduct
organ
prolong
period
viral
rna
detect
semen
one
year
zikv
infect
thu
vaccin
reduc
viral
load
reproduct
organ
like
effect
reduc
viru
transmiss
sexual
contact
importantli
result
show
ediii
formul
use
alum
mpl
combin
significantli
reduc
viral
rna
test
zikvchalleng
mice
therebi
confirm
adjuv
combin
like
yield
greater
vaccin
efficaci
singl
adjuv
alon
contrast
ediii
alon
without
adjuv
result
highest
viral
titer
viral
rna
copi
sera
tissu
test
among
vaccin
group
includ
reproduct
organ
slightli
lower
pbsinject
control
mice
shown
protect
zikv
infect
posit
correl
serum
neutral
antibodi
titer
thu
highlevel
zikv
ediii
aloneimmun
mice
identifi
may
partial
due
rel
low
serum
neutral
antibodi
titer
induc
mice
note
ediii
protein
use
studi
fuse
ctermin
hfc
tag
fcfusion
protein
approv
fda
human
therapi
safeti
pharmacokinet
activ
evalu
extens
fusion
fc
tag
recombin
protein
may
promot
protein
form
dimer
structur
significantli
improv
solubl
stabil
avid
well
increas
immunogen
andor
efficaci
fcfuse
vaccin
design
appli
subunit
vaccin
hiv
influenza
viru
ebola
viru
emerg
reemerg
virus
term
zikv
vaccin
fcfuse
e
protein
dimer
zefc
shown
mimic
nativ
dimer
statu
e
protein
induc
higher
neutral
antibodi
monomer
e
protein
without
fc
monz
also
found
hfcfuse
zikv
ediii
protein
form
dimer
structur
capabl
elicit
hightit
antibodi
respons
neutral
antibodi
protect
highdos
zikv
infect
figur
consist
previou
find
conclus
use
immunocompet
balbc
mice
compar
immunogen
neutral
activ
protect
efficaci
inject
antibodi
zikv
ediii
subunit
vaccin
formul
differ
adjuv
individu
combin
although
ediii
formul
alum
mpl
induc
specif
antibodi
cellular
immun
respons
reduc
viral
load
greatest
vaccin
efficaci
achiev
alum
mpl
adjuv
combin
singl
vaccin
overal
studi
identifi
alum
combin
mpl
adjuv
choic
zikv
subunit
vaccin
import
implic
subunit
vaccin
envelop
virus
includ
nonzikv
flavivirus
author
contribut
ld
cs
initi
design
studi
xw
wt
xz
perform
experi
analyz
data
yz
ld
cs
wrote
edit
approv
manuscript
fund
research
fund
nation
institut
health
nih
grant
intramur
fund
new
york
blood
center
zikv
strain
obtain
bei
resourc
author
declar
conflict
interest
